Search

Search Results

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1671

  PDF: 903

  HTML: 357

• Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)

  NICOLA SGHERZA, Paola Curci, Rita Rizzi, Angela Maria Vittoria Larocca, Luigi Vimercati, Silvio Tafuri, Maria Chironna, Pellegrino Musto

  e2023011

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.011

  1082

  PDF: 1041

  HTML: 512

• Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

  NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto

  e2022056

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.056

  1287

  HTML: 321

  PDF: 568

• “Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Hemolysis by Hemolysis and G6PD deficiency.

  NICOLA SGHERZA, Lidia Dalfino, Antonio Palma, Angelantonio Vitucci, Daniela Campanale, Salvatore Grasso, Pellegrino Musto

  e2020076

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.076

  2000

  PDF: 1065

  HTML: 399

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  846

  PDF: 1215

  HTML: 109